Purchase this article with an account.
Peter M Kaiser, Sumit Sharma, Careen Y. Lowder, Kimberly Baynes, Sunil K Srivastava; Long term outcomes and pharmacokinetics of the injectable fluocinolone acetonide in the treatment of non-infectious uveitis.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3204 – A0430.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Evaluate the long-term effectiveness of the injectable fluocinolone acetonide (FA) implant in patients for the treatment of non-infectious uveitis.
This is a retrospective chart review study of patients enrolled from a single site in 2 multi-centered clinical trials of the FA implant (Psividia 1 and Psivida 6). The number of rescues (defined as intravitreal steroid injections or replacement injectable or surgical FA implants) and the number of flares post implant were collected. Eyes were then categorized into successes if no rescues were required for a minimum of two years.
14 eyes of 12 patients with noninfectious uveitis were included in analysis. The mean age was 54.6 years (range 39-72). There were 10 females (83%). 2 eyes received a sham injection and were thus removed from analysis. Of the 14 analyzed eyes 9 were successes. Amongst the eyes classified as successes, 5 of the 9 have not required rescues to date, with an average time of follow up of 77.1 months. The average time to first rescue amongst successes was 52 months. The average time to first rescue for all patients was 22 months and 8.5 months for the eyes classified as failures. The two sham eyes had an average time to first rescue of 2.25 months.
The injectable FA implant is an effective treatment for noninfectious uveitis. Approximately two thirds of eyes which received the injectable FA successfully reached two years without rescue and 5 out of 9 (55.5%) of the successes did not require rescues five or more years after initial implant injection with regular follow-up. The injectable FA implant can provide several year control for some patients with chronic non-infectious posterior uveitis.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.
This PDF is available to Subscribers Only